Compare Sanofi (SNY) vs Merck & Co., Inc. (MRK) Stock

Merck & Co., Inc. (MRK) offers the better valuation at 17.0x trailing P/E (24.0x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co., Inc. (MRK) is the cheapest at 17.0x versus Sanofi at 20.3x. On forward P/E, Sanofi is actually cheaper at 11.5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Merck & Co., Inc. (MRK) delivered a total return of +100.7%, compared to +28.0% for Sanofi (SNY). A $10,000 investment in MRK five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRK returned +210.2% versus SNY's +70.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sanofi (SNY) is the lower-risk stock at 0.35β versus Merck & Co., Inc.'s 0.43β — meaning MRK is approximately 22% more volatile than SNY relative to the S&P 500.

Merck & Co., Inc. (MRK) is the more profitable company, earning 28.1% net margin versus 16.7% for Sanofi — meaning it keeps 28.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 41.2% versus 13.6% for SNY. At the gross margin level — before operating expenses — MRK leads at 81.5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 11.5x forward P/E versus 24.0x for Merck & Co., Inc. — 12.6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 17.2% to $57.02.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Merck & Co., Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43), +210.2% 10Y return). Both have compounded well over 10 years (MRK: +210.2%, SNY: +70.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SNY is a mid-cap quality compounder stock; MRK is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.